Black Diamond Therapeutics Inc.

11/29/2021 | Press release | Distributed by Public on 11/29/2021 20:26

Initial Statement of Beneficial Ownership (Form 3)

Ownership Submission
FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104Expires:January 31, 2005Estimated average burden hours per response...0.5
1. Name and Address of Reporting Person *
Jones Erika
2. Date of Event Requiring Statement (Month/Day/Year)
2021-11-18 		3. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [BDTX]
(Last) (First) (Middle)
C/O BLACK DIAMOND THERAPEUTICS, INC. , ONE MAIN STREET, 10TH FLOOR
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
See Remarks /
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)
CAMBRIDGE MA 02142
6. Individual or Join/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security 2. Amount of Securities Beneficially Owned 3. Ownership Form: Direct (D) or Indirect (I) 4. Nature of Indirect Beneficial Ownership
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security 2. Date Exercisable and Expiration Date 3. Title and Amount of Securities Underlying Derivative Security 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) 6. Nature of Indirect Beneficial Ownership
Date Exercisable Expriation Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Jones Erika
C/O BLACK DIAMOND THERAPEUTICS, INC.
ONE MAIN STREET, 10TH FLOOR
CAMBRIDGE, MA02142

See Remarks

Signatures

/s/ Brent Hatzis-Schoch, Attorney-in-Fact 2021-11-29
**Signature of Reporting Person Date

Explanation of Responses:

(*) If the form is filed by more than one reporting person, see Instruction 5(b)(v).
(**) Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) 25% of the shares subject to this option vested and became exercisable on October 28, 2020, with the reminder vesting in 36 equal monthly installments thereafter.
(2) 25% of the shares subject to this option vested and became exercisable on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter.
(3) 25% of the shares subject to this option shall vest and become exercisable on March 8, 2022, with the remainder vesting in 36 equal monthly installments thereafter.
(4) The shares subject to this option shall vest and become exercisable in two equal annual installments, with the first installment vesting on October 18, 2022.
(5) The shares subject to this option shall vest and become exercisable in two equal annual installments, with the first installment vesting on November 16, 2022.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.